Evidence map›Paper›PMID 42527713›Full record

ArticleNeuromolecular medicine2026

LncRNA DLX6-AS1 Regulates the Pathological Process Related to Alzheimer's Disease via miR-204-5p.

Minggang Jiang, Yang Lin, Liping Wang, Kaiyun Ou

Abstract read
PubMed Publisher
In one paragraph

Article in Neuromolecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Minggang JiangDepartment of Psychiatry, The Fourth People's Hospital of Jiande, 311612, Hangzhou, China.
Yang LinDepartment of Neurology, Baotou City Central Hospital, 014040, Baotou, Inner Mongolia, China.
Liping WangDepartment of Neurology, The Air Force Hospital of Southern Theater Command, PLA, 510602, Guangzhou, Guangdong, China.
Kaiyun OuDepartment of Neurology, The People's Hospital of Laibin, No. 159 East Pangu Avenue, 546100, Laibin, Guangxi, China. Oukaiyundr@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder causing progressive neuronal damage. Incidence rises with age, and early diagnosis is difficult. This study examined DLX6-AS1 clinical relevance and regulatory mechanism in AD, and its interaction with miR-204-5p in AD pathology. It offers new insights into early diagnosis and treatment. A total of 133 AD patients and 105 healthy controls were selected. Their serum levels of DLX6-AS1 and miR-204-5p were analyzed using quantitative polymerase chain reaction. β-amyloid (Aβ)

Indexed as

Alzheimer DiseaseHomeodomain ProteinsMicroRNAsRNA, Long NoncodingAgedAged, 80 and overAmyloid beta-PeptidesAnimalsBrainCell Line, TumorFemaleHumansMaleMicePeptide FragmentsPhosphorylationAmyloid beta-Peptidesamyloid beta-protein (1-42)DLX6 protein, humanHomeodomain ProteinsMAPT protein, humanMicroRNAsMIR204, humanPeptide FragmentsRNA, Long Noncodingtau ProteinsAlzheimer’s diseaseLncRNAmiRNANeuron damageTau phosphorylation

Identifiers

PMID42527713

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.